GenoScreen is now a certified service provider of Oxford Nanopore Technologies.
Although considered an extinct calamity, leprosy is an infectious disease still present in more than hundred countries.
GenoScreen and Illumina Partner to Expand Access to Genomic Testing for Multidrug-Resistant Tuberculosis
GenoScreen, world specialist in TB genomic solutions, and Illumina partner to expand access to a package combining Deeplex® Myc-TB assay and Illumina sequencing products.
A targeted deep sequencing assay identifies multidrugresistant tuberculosis strains responsible for silent outbreaks
The new edition of the International Symposium on Microbial Ecology a staple meeting in the field, will cover many topics, in environment, human and animal health, and bioprocesses.
For over a decade, GenoScreen has been committed to the fight against tuberculosis (TB), one of the deadliest infectious diseases in the world. The company's journey began with the groundbreaking development of MIRU-VNTR typing kits in 2013 which marked a turning point in TB research and control by enabling rapid and accurate identification of TB strains. This breakthrough technology provided an unparalleled level of resolution in characterizing TB strains, essential for the management and control of TB outbreaks, allowing researchers and public health authorities to track the spread of the disease more efficiently and prevent further outbreaks.
Dr Philip Supply, Director of Research at the CNRS and Scientific Adviser at GenoScreen, has received the prestigious Gardner Middlebrook Lifetime Achievement Award at the 42nd Annual Congress of the European Society of Mycobacteriology (ESM) on 26 June 2022 in Bologna – Italy.